eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
3/2019
vol. 11
 
Share:
Send email
Share:
abstract:
Original paper

Single institution implementation of permanent 131Cs interstitial brachytherapy for previously irradiated patients with resectable recurrent head and neck carcinoma

Voichita Bar-Ad
1
,
Emily Hubley
1
,
Adam Luginbuhl
2
,
David Cognetti
2
,
Joseph Curry
2
,
Amy S Harrison
1
,
Jennifer M Johnson
3
,
James Keller
1
,
Cheng Peng
1
,
David To
4
,
Laura Doyle
1

  1. Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, United States
  2. Department of Otolaryngology, Thomas Jefferson University, Philadelphia, PA, United States
  3. Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, United States
  4. Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, United States
J Contemp Brachytherapy 2019; 11, 3: 227–234
DOI: https://doi.org/10.5114/jcb.2019.85778
Online publish date: 2019/06/13
View full text Get citation
 
Purpose
Permanent interstitial brachytherapy is an appealing treatment modality for patients with locoregional recurrent, resectable head and neck carcinoma (HNC), having previously received radiation. Cesium-131 (131Cs) is a permanent implant brachytherapy isotope, with a low average photon energy of 30 keV and a short half-life of 9.7 days. Exposure to medical staff and family members is low; patient isolation and patient room shielding are not required. This work presents a single institution’s implementation process of utilizing an intraoperative, permanent 131Cs implant for patients with completely resected recurrent HNC.

Material and methods
Fifteen patients receiving 131Cs permanent seed brachytherapy were included in this analysis. The process of pre-planning, selecting the dose prescription, seed ordering, intraoperative procedures, post-implant planning, and radiation safety protocols are described.

Results
Tumor volumes were contoured on the available preoperative PET/CT scans and a pre-implant treatment plan was created using uniform source strength and uniform 1 cm seed spacing. Implants were performed intraoperatively, following tumor resection. In five of the fifteen cases, intraoperative findings necessitated a change from the planned number of seeds and recalculation of the pre-implant plan. The average prescription dose was 56.1 ±6.6 Gy (range, 40-60 Gy). The average seed strength used was 2.2 ±0.2 U (3.5 ±0.3 mCi). Patients returned to a recovery room on a standard surgical floor and remained inpatients, without radiation safety restrictions, based on standard surgical recovery protocols. A post-implant treatment plan was generated based on immediate post-operative CT imaging to verify the seed distribution and confirm delivery of the prescription dose. Patients were provided educational information regarding radiation safety recommendations.

Conclusions
Cesium-131 interstitial brachytherapy is feasible and does not pose major radiation safety concerns; it should be considered as a treatment option for previously irradiated patients with recurrent, resectable HNC.

keywords:

interstitial, brachytherapy, cesium-131, head and neck cancer, salvage treatment

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.